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OBJECTIVE— To evaluate vitamin D as a predictor of all-cause and cardiovascular mortality
and risk of progression to micro- or macroalbuminuria in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS— In a longitudinal observational follow-up
study, 289 type 2 diabetic patients with normoalbuminuria (n 172), microalbuminuria (n
73), and macroalbuminuria (n  44) at baseline were followed for a median (range) of 15.0
(0.2–23) years. Mean  SD age was 54  9 years. Plasma 25-hydroxyvitamin D3 levels were
determined by high-performance liquid chromatography/tandem mass spectrometry on baseline
samples. Severe vitamin D deficiency was defined as the lower 10th percentile (13.9 nmol/l).
RESULTS— Median (range) vitamin D level was 35.7 (5–136.7) nmol/l. Vitamin D levels
were not associated with age, sex, estimated glomerular filtration rate, urinary albumin excretion
rate (UAER), or A1C at baseline, but low levels were weakly associated with elevated systolic
blood pressure (R  0.13, P  0.03). During follow-up, 196 (68%) patients died. All-cause
mortality was increased in patients with severe vitamin D deficiency (hazard ratio 1.96 [95% CI
1.29–2.98]). The association persisted after adjustment for UAER, A1C, diabetes duration, and
conventional cardiovascular risk factors (2.03 [1.31–3.13]). Severe vitamin D deficiency was
associated with increased cardiovascular mortality (1.95 [1.11–3.44]), and the association per-
sisted after adjustment (1.90 [1.15–3.10]). Severe vitamin D deficiency at baseline did not
predict progression to micro- or macroalbuminuria.
CONCLUSIONS— In type 2 diabetic patients, severe vitamin D deficiency predicts increased
risk of all-cause and cardiovascular mortality, independent of UAER and conventional cardiovascular
risk factors. Whether vitamin D substitution improves prognosis remains to be investigated.
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L evels of vitamin D (25-hydroxyvita-min D3 [25(OH)D3]) vary consider-ably among individuals mainly
because of differences in sun exposure
and skin color and the presence of risk
factors such as diabetes or other comor-
bidities. Hypovitaminosis is highly prev-
alent worldwide (1).
The association between vitamin D
and survival primarily originated from
observational studies of dialysis cohorts
receiving therapy with a vitamin D receptor
analog (VDRA) (2). Recently, low levels of
vitamin D have been associated with an in-
creased risk of cardiovascular disease
(CVD) (3) as well as all-cause (4) and car-
diovascular mortality (5) in the general
population.
An observational study on patients
with mainly nondiabetic chronic kidney
disease (CKD) stage 2–5 showed that low
levels of vitamin D independently predicted
death from all-cause and cardiovascular
causes (6). Findings from the same study
support the hypothesis of vitamin D defi-
ciency playing a role in progression to end-
stage renal disease (ESRD).
In the general population, an inverse
association was found between vitamin D
levels and the prevalence of albuminuria
(7). Data from studies in experimental di-
abetic nephropathy and other kidney dis-
ease, as well as limited human evidence,
indicate that vitamin D insufficiency may
be involved in the pathogenesis of albu-
minuria (8,9).
Diabetes is the leading cause of ESRD
in the Western world, and many diabetic
patients will die of cardiovascular compli-
cations. Early identification of increased
renal as well as vascular risk paves the way
for early intervention, thereby contribut-
ing to a desirable reduction in incidents of
CVD and nephropathy among diabetic
patients.
Therefore, we aimed to investigate
whether plasma vitamin D has a prognos-
tic value in predicting increased risk of
excess all-cause and cardiovascular mor-
tality as well as in initiation and/or pro-
gression of diabetic kidney disease in type
2 diabetic patients.
RESEARCH DESIGN AND
METHODS— The study population
was based on all subjects (n  363) with
type 2 diabetes who were aged66 years
and attending a tertiary referral center at
Hvido¨re Hospital during 1987 as de-
scribed previously (10). Type 2 diabetes
was defined as either 1) diabetes treated
by diet alone or by diet combined with
oral hypoglycemic agents, 2) diabetes
treated with insulin plus onset of diabetes
at age40 years and BMI above normal at
the time of diagnosis, or 3) diabetes
treated with insulin, with patients having
a normal BMI and a glucagon-stimulated
C-peptide value 0.60 pmol/ml. Origi-
nally, 31 non-Caucasian patients and 4
patients lacking baseline urine collections
were excluded. In addition, we excluded
39 patients for whom samples for mea-
surement of plasma 25(OH)D3 were not
available at baseline. The cohort thus con-
sisted of 289 patients, mean age 54 years.
Patients were classified as having nor-
moalbuminuria (n 172, urinary albumin
excretion [UAE]30 mg/24 h), microalbu-
minuria, (n 73, UAE 30–299 mg/24 h),
or macroalbuminuria (n 44, UAE300
mg/24 h) at baseline.
In a prospective observational study
design, patients were followed until 31
December 2009 or until death (n  196)
or emigration (n 3). The study was ap-
proved by the local ethics committee and
conducted in accordance with the Decla-
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ration of Helsinki, and all patients gave
their informed written consent.
Baseline clinical and laboratory
investigations
Patients were interviewed using the
World Health Organization cardiovascu-
lar questionnaire (11). Prior major car-
diovascular events were defined as a
history of stroke and/or myocardial
infarction.
Smoking was defined as individuals
smoking 1 cigarettes/cigars/pipes per
day; all others were classified as non-
smokers. UAE rate (UAER) was measured
by radioimmunoassay from 24-h urine
collections. Blood samples were drawn
with patients in the nonfasting state.
A1C levels were determined by an
isoelectric focusing method (normal
range: 4.1–6.1%) (12), serum creatinine
by a kinetic Jaffe´ method, and serum cho-
lesterol by standard methods. Glomerular
filtration rate (GFR) was estimated by the
four-variable Modification of Diet in Re-
nal Disease equation (http://www.nkdep.
nih.gov/professionals/gfr_calculators/
idms_si.htm).
Measurements of plasma 25(OH)D3
After the patients had been at rest for at
least 10 min in the supine position, blood
samples for determination of plasma
25(OH)D3 were collected in citrated
tubes and centrifuged, and plasma was
stored at80°C. All samples were treated
and stored under the same conditions.
Plasma 25(OH)D3 is found to be stable
when tested after 10 years of storage
(13), making long-term epidemiological
studies of plasma 25(OH)D3 possible. Be-
fore initiating the present study, we also
tested the stability of plasma vitamin D in
samples taken from a cohort of type 1 di-
abetic patients followed with regular sam-
pling since 1979 and stored under similar
conditions. We analyzed vitamin D in
samples taken from the same subjects at
the same time of year and stored for 5, 10,
15, 20, and 25 years. No statistically sig-
nificant difference between mean levels of
plasma vitamin D was shown (data not
shown). Plasma levels of 25(OH)D3 were
determined by high-performance liquid
chromatography/tandem mass spectrom-
etry (Department of Clinical Biochemis-
try, Lillebaelt Hospital, Vejle, Denmark).
The coefficients of variation were 12.5%
for a sample of 20 nmol/l, 8.3% for a sam-
ple of 56 nmol/l, and 6.7% for a sample of
231 nmol/l.
Follow-up
All patients were traced through the Na-
tional Register during January 2010. If a
patient had died before 1 January 2010,
the date of death was recorded. Informa-
tion on the cause of death was obtained
from the death certificate until 2004 but
was not available thereafter; thus, cardio-
vascular mortality was evaluated until
2004. All death certificates were reviewed
independently by two observers, and the
primary cause of death was recorded. All
deaths until 2004 were classified as cardio-
vascular deaths unless an unequivocal non-
cardiovascular cause was established (14).
Statistical analysis
Variables with skewed distribution are
given as medians (interquartile range);
data for all other variables are means 
SD. For nonnormally distributed vari-
ables, comparisons between groups were
performed using the Mann-Whitney U
test, whereas unpaired Student t tests
were used for comparisons among nor-
mally distributed variables. A 2 test was
used for comparison of categorical vari-
ables between groups.
To evaluate whether vitamin D is a
predictor of all-cause and cardiovascular
mortality in an explanatory model, a Cox
proportional hazards regression model
was used. The relationships were first an-
alyzed without adjustment, followed by
an adjustment for baseline variables (sex,
age, smoking, systolic blood pressure,
history of cardiovascular disease, dura-
tion of diabetes, total cholesterol, and kid-
ney function (estimated GFR [eGFR] and
UAER), all of which have previously been
shown to be associated with increased all-
cause and cardiovascular mortality.
Using the Cox proportional hazards
regression model, we did additional uni-
and covariate analysis on the cohort when
it was divided according to the median
diabetes duration of the group with low
vitamin D levels (11 years). Results are
presented as hazard ratios (HR) with 95%
CI. All time-to-event variables were ana-
lyzed with a log-rank test and displayed as
Kaplan-Meier plots according to levels of
vitamin D either greater than or less than
the 10th percentile. Two-tailed P  0.05
was considered statistically significant.
All statistical calculations were performed
using SPSS for Windows (version 14.0;
SPSS, Chicago, IL).
RESULTS— The main baseline char-
acteristics of the patients are given in Ta-
ble 1. The median (range) vitamin D
concentration was 35.7 (5–136.7) nmol/l.
The patients were divided into two sub-
Table 1—Baseline clinical and laboratory characteristics of 289 type 2 diabetic patients
according to levels of 25(OH)D3
25(OH)D3
13.9 nmol/l
25(OH)D3
13.9 nmol/l P value
n 260 29
Sex (male/female) 161/99 16/13 0.55
Age (years) 53.7  8.9 54.6  9.6 0.59
Known duration of diabetes (years) 6 (2.0–11.0) 11 (6.5–15.5) 0.001
Retinopathy (nil/simplex/proliferative) 179/72/9 12/14/3 0.03
History of cardiovascular disease 23 (9) 3 (10) 0.73
Antihypertensive medication 98 (38) 10 (34) 0.84
BMI (kg/m2) 28.6  4.9 27.5  5.5 0.25
HbA1c (%) 8.0  1.8 8.6  1.8 0.1
Nephropathy (normo/micro/
macroalbuminuria) 158/66/36 14/7/8 0.14
UAER (mg/24 h) 18 (7–65.5) 31 (6–364) 0.03
Serum creatinine (mol/l) 74 (64–88) 70 (62–90) 0.85
eGFR (ml/min per 1.73 m2) 93  26 89  29 0.48
Systolic blood pressure (mmHg) 150  23 154  24 0.32
Diastolic blood pressure (mmHg) 86  12 82  15 0.2
Serum cholesterol (mmol/l) 6.3  1.6 6.1  1.7 0.53
Serum HDL cholesterol (mmol/l) 1.2  1.0 1.3  1.7 0.63
Serum triglycerides (mmol/l) 1.85 (1.27–2.84) 1.45 (1.08–2.4) 0.24
Smokers (%) 43.1 48.3 0.69
25(OH)D3 (nmol/l) 38.6 (24.2–57.9) 11.0 (5.0–12.7) —
Data are n, means  SD, n (%), or medians (interquartile range).
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groups based on their vitamin D level at
baseline being either in the lower 10th
percentile or above. The cutoff value for
the lower 10th percentile was vitamin D
13.9 nmol/l in both men and women.
Patients with low levels of vitamin D had
more advanced retinopathy (P 0.03), a
higher UAER (P  0.03), and a longer
known duration of diabetes (P  0.001),
but vitamin D levels were not associated
with diabetes duration (R  0.07, P 
0.26). Vitamin D levels were not associ-
ated with age, sex, eGFR, UAER, or A1C
at baseline, but low levels were weakly
associated with elevated systolic blood
pressure (R  0.13, P  0.03).
During 15 (0.2–23) years of follow-
up, 196 (68%) of the 289 patients died.
Figure 1A shows Kaplan-Meier curves for
all-cause mortality in patients according
to a vitamin D level less than or greater
than the lower 10th percentile. During
follow-up, all-cause mortality was signif-
icantly increased in patients with severe
vitamin D deficiency: 25 (86%) patients
with vitamin D 13.9 nmol/l and 171
(66%) patients with vitamin D 13.9
nmol/l died (P 0.01). In a Cox propor-
tional hazards model the unadjusted HR
(95% CI) was 1.96 (1.29–2.98). The as-
sociation persisted after adjustment for
UAER, eGFR, A1C, diabetes duration,
and conventional cardiovascular risk fac-
tors (adjusted HR 2.03 [1.31–3.11]).
Known duration of diabetes at baseline
was significantly different in groups ac-
cording to levels of vitamin D, being
longer in the patient group with low levels
of vitamin D. Therefore, duration was ad-
justed for in the Cox models. Table 2
shows crude and adjusted HRs for predic-
tors of all-cause mortality used in the Cox
proportional hazards model.
Until 2004, 101 (72%) of the ob-
served 141 deaths were due to cardiovas-
cular causes. Of these, 14 patients had
vitamin D 13.9 nmol/l and 87 patients
had vitamin D levels above the 10th per-
centile (P  0.02). Cardiovascular mor-
tality according to a vitamin D level less
than or greater than the lower 10th percen-
tile is illustrated in Fig. 1B. Severe vitamin D
deficiency was associated with increased
cardiovascular mortality (unadjusted HR
1.95 [1.11–3.44] and after adjustment HR
1.90 [1.16–3.10]).
Dividing the entire cohort according
to known duration of diabetes presented
two new subgroups: a group consisting of
patients with diabetes duration11 years
(n  212) and a group consisting of pa-
tients with a diabetes duration of 11
years (n  77). During follow-up until 1
January 2010, 137 (65%) and 59 (77%)
patients, respectively, in the two groups
died. Despite reduced power, the analysis
shows a similar trend for low levels of vi-
tamin D being predictive of all-cause mor-
Figure 1—A: Kaplan-Meier curves of all-cause mortality in 289 type 2 diabetic patients accord-
ing to a vitamin D level less than or greater than the lower 10th percentile [25(OH)D3  13.9
nmol/l].——, 25(OH)D313.9 nmol/l;     , 25(OH)D313.9 nmol/l. Log-rank test for overall
difference, P 0.002. B: Kaplan-Meier curves of cardiovascular mortality in 289 type 2 diabetic
patients according to a vitamin D level less than or greater than the lower 10th percentile
[25(OH)D3  13.9 nmol/l]. ——, 25(OH)D3 13.9 nmol/l;     , 25(OH)D3 13.9 nmol/l.
Log-rank test for overall difference, P  0.015.
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tality in both groups. Although weakened
and no longer significant in either group,
the trend slightly stronger in patients with
a long duration of diabetes (Table 2).
An analysis of vitamin D as a contin-
uous variable in the Cox model could not
demonstrate a significant relation to all-
cause or cardiovascular mortality, sug-
gesting that the relationship is not linear
over the range of vitamin D values.
Progression to microalbuminuria
and macroalbuminuria
The patients were followed until 2004 in
regards to progression in albuminuria.
Among the 172 normoalbuminuric pa-
tients at baseline, 61 patients developed
persistent microalbuminuria during fol-
low-up. A Cox proportional hazards
model revealed that low vitamin D levels
at baseline did not predict development of
microalbuminuria (unadjusted HR 0.72
[0.31–1.70]).
Among the 73 microalbuminuric pa-
tients at baseline, 25 patients developed
persistent macroalbuminuria during fol-
low-up. Of the 25 patients who pro-
gressed, 23 had vitamin D levels above the
lowest 10% percentile and 2 had lower
vitamin D levels (unadjusted HR 3.52
[0.74–16.71]). After adjustment for pro-
gression promotors, the association
weakened further.
CONCLUSIONS— In our 15-year
longitudinal observational follow-up
study, we found very low levels of plasma
vitamin D (less than the 10th percentile)
to be a strong and independent predictor
of all-cause mortality in type 2 diabetic
patients. Low levels of vitamin D were
also predictive of cardiovascular mortal-
ity. These associations were not only in-
dependent of glycemic control and
conventional cardiovascular risk factors
including known ischemic heart disease
but also were independent of kidney
function.
Severe vitamin D deficiency at base-
line did not predict progression to mi-
croalbuminuria or macroalbuminuria.
Our findings of associations between se-
vere vitamin D deficiency and increased
risk of all-cause and cardiovascular mor-
tality in type 2 diabetic patients comple-
ment recent data from studies suggesting
similar associations in the general popu-
lation (4) and among patients with non-
diabetic CKD (6) or ESRD (15).
A cross-sectional study on 13,331
participants from NHANES III found low
vitamin D levels to be associated with all-
cause mortality (4). Furthermore, a fol-
low-up study on 1,739 Framingham
Offspring Study participants showed that
the incidence of nonfatal cardiovascular
events was increased among participants
with low vitamin D levels (3). A study on
mainly nondiabetic patients with CKD
found vitamin D to independently predict
all-cause mortality, cardiovascular events,
and increased risk of progression to dial-
ysis (6).
Vitamin D is stored in its inactive
form in the liver and in peripheral fat tis-
sue for the body to extract and activate by
hydroxylation in the liver and kidney, re-
spectively. In healthy subjects, vitamin D
deficiency can result from inadequate in-
take of vitamin D–containing foods cou-
pled with inadequate sunlight exposure.
Seasonal variations in vitamin D levels oc-
cur, depending on geographic latitude
and sun exposure in particular. A study
done on the general population in a
Northern European country showed a
seasonal variation of vitamin D insuffi-
ciency of 73 and 29% for winter and sum-
mer, respectively. The difference for
vitamin D deficiency was similarly found
to be 8 and 1% (16). Furthermore, there
are several conditions, such as obesity,
absorption, and liver or kidney disorders,
in which the risk of developing vitamin D
deficiency is increased for physiological
reasons.
Obesity is common among patients
with type 2 diabetes. Vitamin D stored
in fat tissue causes decreased bioavailabil-
ity, and exposes obese patients at greater
risk of developing vitamin D insuffi-
ciency. However, in the present study, the
patients in the two subgroups did not dif-
fer significantly in BMI. There is no linear
association between BMI and vitamin D in
these data. Diabetic patients are more
prone to developing CVD compared with
the general population (17). Having a
higher risk profile, a greater treatment po-
tential exists if vitamin D is also found to
be a risk factor for CVD development and
mortality.
The role of vitamin D deficiency in
prevalent cardiovascular disease is in a
cross-sectional study of type 2 diabetic
patients with mild kidney impairment,
shown to be strongly associated with a
higher prevalence of manifest cardiovas-
cular disease, also after adjustment for
baseline kidney function and other
known CVD risk factors (18).
With the present longitudinal fol-
low-up study we are now able to show
that the predictive value of low vitamin D
levels on all-cause and cardiovascular
mortality, already shown for the general
Table 2—Crude and adjusted HRs for predictors of all-cause mortality
Predictors of all-cause mortality HRcrude (95% CI) HRadj (95% CI)
HRadj (95% CI), diabetes
duration 11 years*
HRadj (95% CI), diabetes
duration 11 years*
n 212 77
Age (years) 1.08 (1.06–1.11) 1.06 (1.05–1.10) 1.09 (1.06–1.12) 1.07 (1.02–1.11)
Sex (female vs. male) 0.73 (0.55–0.98) 0.76 (0.55–1.05) 0.95 (0.65–1.41) 0.68 (0.37–1.27)
History of cardiovascular disease 3.63 (2.38–5.54) 3.29 (2.11–5.12) 3.72 (2.10–6.59) 2.18 (1.02–4.65)
Systolic blood pressure (mmHg) 1.02 (1.01–1.03) 1.01 (1.01–1.02) 1.01 (1.00–1.02) 1.00 (0.99–1.02)
Cholesterol (mmol/l) 1.12 (1.03–1.22) 1.08 (0.99–1.18) 1.22 (1.08–1.40) 0.99 (0.84–1.16)
eGFR (ml/min per 1.73 m2) 0.98 (0.98–0.99) 1.00 (0.99–1.00) 0.99 (0.99–1.00) 0.99 (0.98–1.01)
UAER (mg/24 h) 1.61 (1.37–1.90) 1.54 (1.28–1.85) 1.67 (1.32–2.13) 1.45 (1.05–1.97)
Smoking (yes vs. no) 1.03 (0.77–1.36) 1.41 (1.05–1.89) 1.87 (1.30–2.68) 0.94 (0.52–1.68)
Diabetes duration (years) 1.02 (1.01–1.04) 1.01 (0.99–1.02) — —
Vitamin D, lowest 10th percentile 1.96 (1.29–2.98) 2.03 (1.31–3.13) 1.58 (0.83–3.03) 2.87 (1.41–5.87)
Columns 2 and 3 show crude and adjusted HRs, respectively, for predictors of all-cause mortality. Columns 4 and 5 show HRs for predictors of all-cause mortality
when the cohort is divided according to diabetes duration. *Divided according to median diabetes duration in the patients with vitamin D levels less than the lowest
10th percentile.
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population and in patients with nondia-
betic CKD, also applies to type 2 diabetic
patients.
The mechanisms of action behind the
survival benefit seen among patients with
the higher levels of vitamin D at baseline are
unclear. A growing amount of evidence in-
dicates that vitamin D through activation of
the vitamin D receptor has clinically impor-
tant pleiotropic effects involved in CVD de-
velopment and mortality. Vitamin D has
been associated with suppression of the re-
nin-angiotensin-aldosterone system
(RAAS) (19), cardiac myocyte hypertrophy
(20), vascular calcification, atherosclerosis-
lowering, anti-inflammatory (21), and im-
munomodulatory actions (1), suggesting
cardiovascular and renoprotective effects.
Furthermore, vitamin D deficiency has
been associated with increased incident risk
of certain cancers as well as a higher mortal-
ity from these cancers (1).
Several of the above-mentioned path-
ways may be important mechanisms in
cardiovascular health. Inflammation is a
key mechanism in atherosclerosis. A re-
cent study in type 2 diabetic patients, in-
vestigating the mechanism by which
vitamin D deficiency mediates increased
risk of cardiovascular disease, found re-
duced vitamin D receptor signaling to be a
potential mechanism underlying in-
creased foam cell (macrophages who in-
gested oxidized LDL) formation and
accelerated cardiovascular disease in dia-
betic compared with nondiabetic patients
(22).
Given the observational design, the
present study does not elaborate further
on underlying mechanisms but adds to
the increasing amount of data suggesting
that vitamin D substitution might be a po-
tential therapeutic target to prevent vas-
cular disease progression. In this study
there was a significant difference in
known diabetes duration between groups
with low and higher levels of vitamin D,
but duration of diabetes and level of vita-
min D were not associated and we ad-
justed for known duration of diabetes in
our Cox models. In a type 1 diabetes co-
hort, we have recently presented a similar
predictive effect of low vitamin D levels
(C.J., personal communication, American
Society of Nephrology, 2009). Analysis of
subgroups based on duration of diabetes
of more or less than 11 years, suggested
that the effect was stronger in patients
with long duration; however, because of
the reduced power, such analysis should
be interpreted with caution.
The pathogenesis behind diabetic
kidney disease is complex and thought to
involve multiple pathways. Of particular
importance is an activation of the intrare-
nal RAAS promoting progressive renal in-
jury. In mice, 1,25-dihydroxyvitamin D3
is shown to be a negative endocrine reg-
ulator of the RAAS on transcriptional level
independent of calcium and PTH (19).
Agarwal et al. (9) analyzed data from three
randomized controlled clinical trials in-
vestigating administration of oral parical-
citol in patients with CKD. They showed
that paricalcitol caused a reduction in al-
buminuria as measured by a dipstick
method compared with placebo (P 
0.004). Importantly, the effects seemed to
be independent of concomitant therapies
to inhibit the RAAS. Furthermore, it has
recently been shown that administration
of a VDRA in addition to blockade of the
RAAS causes sustained albuminuria re-
duction and thereby has clinically rele-
vant renoprotective effects in patients
with CKD (23) (D. de Zeeuw, personal
communication, American Society of
Nephrology, 2009).
Because of circumstantial evidence on
the beneficial effects seen when one is in-
tervening with VDRA, it is tempting to
speculate that low levels of vitamin D
might be a risk marker of both initiation
and/or progression of albuminuria in di-
abetic patients (9). Our study, however,
did not find vitamin D levels 13.9
nmol/l to significantly predict either initi-
ation or progression of albuminuria.
In our study, severe vitamin D defi-
ciency was defined as the lower 10th per-
centile [25(OH)D313.9 nmol/l] in both
men and women. An international con-
sensus in regard to definitions of which
vitamin D levels are to be thought of as
normal, insufficiency, and deficiency is
lacking. The limits for a physiological op-
timal vitamin D level are still a matter of
debate in the literature. Although vitamin
D is shown to be stable in stored samples
(13), storing could affect absolute con-
centrations due to evaporation; thus, we
chose the 10th percentile. As mentioned,
the stability of plasma vitamin D levels in
our samples was tested before analysis
was done on the present cohort and found
not to show any statistically significant
difference in levels when samples from
different years of storage were compared.
Our study has some strengths and
limitations. One element of methodolog-
ical strength is the longitudinal design
and long follow-up period and complete-
ness of follow-up. Given the observa-
tional design, it is not possible to infer
causality from the associations described.
Secondary hyperparathyroidism in
patients with CKD is known to predict
increased all-cause and cardiovascular
mortality (24). The question arises
whether the observed predictive effect of
vitamin D is merely to be considered as a
marker for other associated risk factors.
We did not measure parathyroid hor-
mone at baseline, and therefore we were
not able to exclude this vitamin D-
dependent variable as a driving con-
founder in our analysis. However, kidney
function was adjusted for, and still the
association between vitamin D and in-
creased mortality persisted.
Further limitations of our study are re-
lated to possible changes in the level of vi-
tamin D throughout the year. We did not
adjust for seasonal change nor did we have
baseline data on physical activity that could
be related to outdoor activity and sun expo-
sure and thereby level of vitamin D. We
were therefore not able to adjust for this.
More observational studies are
needed to confirm our findings. Random-
ized controlled clinical trials administer-
ing VDRA are necessary to prove causality
between vitamin D status and survival
prognosis in diabetic patients.
In summary, baseline levels of
25(OH)D3 less than the 10th percentile pre-
dict increased risk of all-cause and cardio-
vascular mortality in type 2 diabetic
patients. Baseline levels of 25(OH)D3 less
than the 10th percentile do not predict pro-
gression to micro- or macroalbuminuria.
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